2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2837

Importance of Mixed Speckled/ Homogeneous DFS70 ANA Patterns
Abstract Number: 3249

Improvement in Cough and Cough-Related Quality of Life in Participants Undergoing Treatment for Systemic Sclerosis-Related Interstitial Lung Disease
Abstract Number: 444

Improvement in Knee Arthrocentesis Via Constant Compression
Abstract Number: 107

Improvement of Quality and Cost-Effectiveness of Rheumatology Care By Creating Long-Term Alliances with Pharmaceutical Companies
Abstract Number: 3010

Improvement of Spinal Inflammation Induced By Etanercept in Enthesitis Related Arthritis JIA-Patients. Data of the Reminder-Study
Abstract Number: 441

Improving Care and Avoiding Errors. Can Our Patients Recall Their Medications and Create an Accurate Medication List?
Abstract Number: 3142

Improving Counseling, Documentation and Adherence to Highly Effective Birth Control in Women on Teratogenic Medications at a Rural Medical Center: A Quality Improvement Initiative
Abstract Number: 425

Improving Pneumococcal Vaccination Rates for Immunosuppressed Patients in an Academic Rheumatology Clinic
Abstract Number: 2306

Improving Predictive Value of Gout Case Definitions in Electric Medical Records Utilizing Natural Language Processing: a Novel Informatics Approach
Abstract Number: 2042

Improving the Overall Pneumococcal Vaccination Rate in Lupus Patients at the Rheumatology Clinic
Abstract Number: 699

In Contrast to Men, Women with Nonradiographic Axial Spondyloarthritis Have Lower Response Rates to TNF Inhibitors Than Women with Ankylosing Spondylitis
Abstract Number: 1376

In Juvenile Dermatomyositis, Organ Damage Is Comparable after Median 13.5 and 21.5 Years Follow-up Time, Despite Sustained Disease Activity
Abstract Number: 701

In Patients with Ankylosing Spondylitis Treated with Adalimumab, Combination Therapy with DMARD, Increase the Serum Level of Adalimumab and Decrease Immunogenicity
Abstract Number: 2487

In Patients with Rheumatoid Arthritis in Clinical Remission Undergoing Treatment Tapering Tenosynovitis and Synovitis Detected By Ultrasonography Predict Disease Flare
Abstract Number: 1626

In Real Life Rheumatoid Arthritis Patients, Leflunomide Has Limited Impact As a Second Line DMARD after Methotrexate

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].